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Abstract
Introduction: Breast carcinoma is the most common cancer in women, but its incidence is not increased in Lynch
syndrome (LS) and studies on DNA mismatch repair deficiency (MMR) in LS-associated breast cancers have arrived
at conflicting results. This study aimed to settle the question as to whether breast carcinoma belongs to the LS
tumor spectrum.
Methods: MMR status and epigenetic profiles were determined for all available breast carcinomas identified
among 200 LS families from a nation-wide registry (23 tumors from mutation carriers and 18 from non-carriers).
Sporadic breast carcinomas (n = 49) and other cancers (n = 105) from MMR gene mutation carriers were studied
for comparison.
Results: The proportion of breast carcinomas that were MMR-deficient based on absent MMR protein, presence of
microsatellite instability, or both was significantly (P = 0.00016) higher among breast carcinomas from mutation
carriers (13/20, 65%) compared to non-carriers (0/14, 0%). While the average age at breast carcinoma diagnosis was
similar in carriers (56 years) and non-carriers (54 years), it was lower for MMR-deficient versus proficient tumors in
mutation carriers (53 years versus 61 years, P = 0.027). Among mutation carriers, absent MMR protein was less
frequent in breast carcinoma (65%) than in any of seven other tumor types studied (75% to 100%). Tumor
suppressor promoter methylation patterns were organ-specific and similar between breast carcinomas from
mutation carriers and non-carriers.
Conclusions: Breast carcinoma from MMR gene mutation carriers resembles common breast carcinoma in many
respects (for example, general clinicopathological and epigenetic profiles). MMR status makes a distinction: over
half are MMR-deficient typical of LS spectrum tumors, while the remaining subset which is MMR-proficient may
develop differently. The results are important for appropriate surveillance in mutation carriers and may be relevant
for LS diagnosis in selected cases.
Introduction
Germline mutation in one of four genes with DNA mis-
match repair (MMR) function, MLH1, MSH2, MSH6,
and PMS2, causes susceptibility to cancers of multiple
organs known as Lynch syndrome (LS) [1]. Among all
cancers, those of the colon and rectum, endometrium,
small bowel, ureter and renal pelvis have the highest
relative risk compared to the general population, which
is why they are considered to be part of the LS tumor
spectrum according to the Amsterdam criteria II [2].
Among extracolonic tumors accepted as LS spectrum
tumors when the Amsterdam II criteria were formu-
lated, cancer of the renal pelvis had the lowest relative
risk (14) [3].
Breast cancer is the most common cancer among
women worldwide [4]. It is presently not included in the
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LS tumor spectrum because its incidence has not been
found to be elevated in LS patients, whether carriers of
MLH1 or MSH2 mutation [5-8] or MSH6 mutation [9].
A few deviating reports exist. A study on Australian LS
patients revealed a significantly increased standardized
incidence ratio (14.77) for breast cancer in MLH1, but
not MSH2 mutation carriers [10]. The standardized inci-
dence ratio for breast cancer was also elevated (3.95) in
a prospective investigation of a cohort of 446 unaffected
carriers of MLH1, MSH2, MSH6, and PMS2 mutation
over a median follow-up of five years [11]. Furthermore,
among Brazilian families meeting the most stringent
clinical (Amsterdam I) criteria for LS [12] but with no
mutation data available, breast cancer was the most fre-
quent extracolonic cancer in women, even exceeding the
frequency of endometrial cancer [13].
As an additional approach to decide whether breast
cancer is a LS spectrum tumor or not, breast cancers
arising in LS patients have been studied for microsatel-
lite instability (MSI) or MMR protein expression since
deficient MMR is a hallmark of LS. As observed origin-
ally, the absence of MMR defects appeared to exclude
breast cancer as an integral tumor of LS [14] whereas
subsequent studies report the occurrence of MMR
defects in breast carcinomas from MMR gene mutation
carriers with frequencies ranging between 44% and 75%
based on MSI and/or aberrant MMR protein expression
[8,15-19]. Frequencies of MMR defects reported in the
latter studies exceed those independently observed for
sporadic breast carcinomas (0 to 20%) [20,21] suggesting
that MMR deficiency is an important factor in breast
cancer development in LS.
Given the conflicting results from previous studies, we
collected all available LS-associated breast carcinomas
through the nation-wide Hereditary Colorectal Cancer
Registry of Finland. Molecular profiles in breast carcino-
mas from mutation carriers were compared to those
from proven non-carriers (phenocopies) from mutation-
positive families and to sporadic breast carcinomas from
the same population; additionally, a large collection of
other LS-associated tumors from mutation carriers was
included in the analysis. Molecularly, breast carcinomas
from LS mutation carriers were divided into two sub-
groups paralleled by some clinical differences (notably,
different ages at onset) as will be described below.
Materials and methods
Patients and samples
The more than 200 LS families currently included in the
nation-wide Hereditary Colorectal Cancer Registry of Fin-
land were evaluated to identify cases with breast cancer.
All available breast tumors including 41 tumors from 37
individuals who belonged to families with MLH1, MSH2,
or MSH6 mutations were subsequently collected (Table
1). Twenty-three breast tumors originated from 19 muta-
tion carriers and included 11, five, and seven tumors from
carriers of MLH1, MSH2, and MSH6 mutation, respec-
tively (please see Table 2 for mutation descriptions). Eigh-
teen breast tumors were obtained from 18 non-carriers
who belonged to families with MLH1 (15 tumors), MSH2
(two tumors), and MSH6 mutations (one tumor). Four
families contributed at least one breast cancer from a car-
rier and one from a non-carrier. Nine breast tumors origi-
nated from carriers of a prevalent founder mutation
(mutation 1) [22] and the same predisposing mutation
underlay the families of ten non-carriers with breast can-
cer. Forty-nine sporadic breast tumors, selected from a lar-
ger consecutive series to represent the two main
histological types, ductal (n = 30) and lobular (n = 19),
and to match the predominant hormone receptor status
(positive) and human epidermal growth factor receptor 2
(HER2) status (negative) of LS-associated breast cancers
were studied for comparison (Table 1). Additionally, exist-
ing data from 105 other tumors (including 33 from the
colon and rectum, 38 from the endometrium, 13 from the
stomach, five from the ureter, five from the bladder, four
from the kidney, and seven from the brain) diagnosed in
MMR gene mutation carriers were re-evaluated for MMR
status and promoter methylation using criteria identical to
those presently applied for breast cancer; detailed charac-
teristics of the tumor series can be found in our previous
publications [23-25].
DNA was extracted from formalin-fixed paraffin-
embedded tumor samples from selected areas with high
tumor percentages according to the modified protocol
of Isola et al. [26]. Normal breast tissue from the same
patients was used for the extraction of normal DNA
whenever possible. Additionally, to determine the base-
line levels of methylation, normal breast tissues from a
cohort of unrelated individuals were used as a source of
DNA. For protein expression studies, 4 μl sections from
breast tumors were cut to glass adhesion slides (Thermo
Scientific, Braunschweig, Germany) and air-dried over-
night at 37°C. The Institutional Review Boards of Hel-
sinki University Central Hospital (Helsinki, Finland) and
Jyväskylä Central Hospital (Jyväskylä, Finland) as well as
the National Authority for Medicolegal Affairs (Dnro
1272/04/044/07) approved this study. All necessary con-
sents were obtained from the patients involved.
MSI analysis
MSI statuses were analyzed using markers from the
Bethesda panel [27]. In final interpretations, results from
the mononucleotide markers (BAT25 and BAT26) were
emphasized in that specimens with one or two unstable
mononucleotide repeat markers were considered to have
MSI whereas samples with stable mononucleotide
repeats were regarded as microsatellite-stable (MSS).
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Immunohistochemical (IHC) staining for MMR protein
expression
Breast tumor tissue sections were stained with the fol-
lowing primary mouse antibodies: anti-MLH1 (clone:
G168-15, BD Biosciences,/PharMingen, Erembodegem,
Belgium) with dilution 1:60, anti-MSH2 (clone:FE11,
Calbiochem,/Oncogene Research, Darmstadt, Germany)
with dilution 1:80, and anti-MSH6 (clone:44/MSH6, BD
Biosciences) with dilution 1:40. The immunohistochem-
ical (IHC) reagents (Dako EnVision+, Dako, Glostrup,
Denmark/Carpinteria CA, USA) were utilized according
to the manufacturer’s specifications. The microwave
antigen-retrieval was performed at 750 W for five min-
utes and 450 W for five minutes in ethylenediaminete-
traacetic acid (EDTA) buffer, pH8 (with MLH1 and
MLH2 antibodies) and in citrate buffer, pH6 (with
MLH6 antibody). The expression results were evaluated
as described in Renkonen et al. [28].
Methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA)
The methylation statuses of 24 tumor suppressor genes
(TSGs) were analyzed by a commercial MS-MLPA test
(SALSA MS-MLPA ME001-C1 Tumor suppressor-1,
MRC Holland, Amsterdam,The Netherlands) according
to the manufacturer’s instructions [29]. The 26 probe
pairs included two probe pairs for MLH1 of which
only the one closest to the transcription start site
(1686–L1266) was considered, and two probe pairs for
RASSF1, where methylation was recorded if one or
both showed methylation. DNA (200 ng to 500 ng)
from paraffin-derived samples was used. Promega’s
human genomic female DNA (G152A, Madison WI,
USA) was included as a normal reference in every
assay. The MS-MLPA test utilizes the methylation sen-
sitive enzyme Hha1 (Promega, R6441) which recog-
nizes and digests a CpG site if it is unmethylated [30].
The methylated fraction of the sample will generate an
amplified PCR product. The PCR products of indivi-
dual probes are identified and quantified by capillary
gel electrophoresis [31]. The fragment analysis was car-
ried out on the Applied Biosystems ABI 3730 Auto-
matic DNA Sequencer with Applied Biosystems
GeneMapper 4.0 genotyping software. The methylation
dosage ratios (Dm) were calculated as described [24].
Dm ≥0.25 (corresponding to at least 25% of methylated
DNA) was considered to indicate promoter methyla-
tion. This cut-off value provided the best





Carriers Non-carriers Sporadic breast cancer
c
No. of tumors 23 18 49
ductal 17 14 30
ductal in situ 2 1 -
lobular 3 - 19
other 1 2 -
no histological data - 1 -
Size (= 20 mm) 7/19 (37%) 9/14 (64%) 30/49 (61%)
G1 2/19 (11%) 4/12 (33%) 12/46 (26%)
G2 10/19 (53%) 5/12 (42%) 29/46 (63%)
G3 7/19 (37%) 3/12 (25%) 5/46 (11%)
Lymph node metastases 6/16 (38%) 7/10 (70%) 28/47 (60%)
Receptor status:
ER-positivity 20/22 (91%) 6/7 (86%) 49/49 (100%)
PR-positivity 15/22 (68%) 5/7 (71%) 41/46 (89%)
HER2-positivity 3/20 (15%) 1/6 (17%) 0/49 (0%)
Average age at diagnosis (years) 56 54 61
MSI 8/23 (35%) 0/18 (0%) N/A
MMR protein reduced or lost 13/20 (65%) a 0/14 (0%) b 0/49 (0%) b
Average number of TSGs methylated out of 24 per
tumor
2.3 2.0 2.4
aFor MMR protein corresponding to the germline mutation; bfor any MMR protein investigated (MLH1, MSH2, MSH6); cClinicopathological data and MMR status
reflect selection method used (see text). Note: All frequency calculations are based on tumors for which data were available or which could be successfully
analyzed in the laboratory. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LS, Lynch Syndrome; MMR, mismatch repair; MSI,
microsatellite instability; PR, progesterone receptor; TSG, tumor suppressor gene.
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discrimination between tumor DNA and paired normal
DNA in the present breast cancer series.
Statistical analysis
Programs from the VassarStats website [32] were used.
The significance level for the differences between groups
(P value) was determined using Fisher’s exact test or
Student’s t test as appropriate. P values <0.05 (two-
tailed) were considered significant.
Results
Study design and clinicopathological characteristics
This study was based on 90 breast carcinomas (23 from
mutation carriers, 18 from non-carriers, and 49 from
sporadic cases) (Table 1) and 105 other tumors from
MMR gene mutation carriers (see Materials and methods
for details). Most breast tumors from mutation carriers
were ductal (17 out of 21 invasive tumors, 81%), estrogen
receptor (ER) positive (91%), progesterone receptor (PR)










MLH1 MSH2 MSH6 Overall
MMR
statusa
Average number of TSGs
methylated out of 24/tumor
2:51 MLH1 ex 16: 3,5 Kb deletion
(mutation I)
ductal in situ 52 MSI - + + abnormal 1
3:60 MLH1 ex 16: 3,5 Kb deletion
(mutation I)
ductal 66 MSS + + + normal 2
10:11 MLH1 ex 16: 3,5 Kb deletion
(mutation I)
ductal 50 MSS - + ND abnormal 0
50:44 MLH1 ex 16: 3,5 Kb deletion
(mutation I)
ductal, left breast 71 MSS + + + normal 1
lobular, right
breast
72 MSS - + ND abnormal 4
62:1 MLH1 ex 16: 3,5 Kb deletion
(mutation I)
ductal + in situ 52 MSI - ND ND abnormal 3




43 MSI - + + abnormal 0
lobular, left
breast
47 MSS - + ND abnormal 1
77:24 MLH1 ex 16: 3,5 Kb deletion
(mutation I)
lobular 51 MSS + + + normal 0
143:1 MLH1 c.454-1G>A, splice site ductal 56 MSI - + + abnormal 3
157:1 MLH1 c1489insC ductal 54 MSI - + + abnormal 4
136:1 MSH2 c.1738insA ductal + in situ 79 MSS ND ND ND ND 2
180:1 MSH2 del ex 1-16 ductal 60 MSS ND ND ND ND 1









48 MSI + - - abnormal 4
197:1 MSH2 c.187delG ductal 55 MSI + - - abnormal 1
132:1 MSH6 c.2983 G>T, nonsense
and CHEK2 c.1100delC
ductal in situ 69 MSS + ND + normal 1
132:2 MSH6 c.2983 G>T, nonsense
and CHEK2 c.1100delC
ductal 35 MSS ND ND ND ND 1
196:1 MSH6 ex1-2 deletion ductal, left breast 52 MSS + + - abnormal 2
ductal, right
breast
56 MSS + + - abnormal 3
196:2 MSH6 ex1-2 deletion ductal 56 MSS + + + normal 2
196:3 MSH6 ex1-2 deletion mucinous 68 MSS + + + normal 2
196:4b MSH6 ex1-2 deletion ductal 49 MSS + + + normal 12
aAbnormal MMR status denotes absence of MMR protein corresponding to the germline mutation, presence of MSI, or both. Normal MMR status requires intact
MMR protein expression relative to germline mutation and stable microsatellites. NOTE: ND, not defined; for IHC, -, protein absent, +, protein present. IHC,
immunohistochemistry; MMR, mismatch repair; MSI, microsatellite instability; TSG, tumor suppressor gene.
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positive (68%) and HER2 negative (85%) and the same
was true for breast tumors from non-carriers. The hor-
mone receptor and HER2 status of the LS-associated ser-
ies resembled those in unselected breast carcinomas
from our population [33]. The average age at diagnosis
was similar in carriers (56 years) and non-carriers (54
years).
MMR status
Detailed molecular data on breast carcinomas from
mutation carriers are shown in Table 2. MMR protein
corresponding to the germline mutation was reduced
or lost in 13/20 (65%) and MSI was present in 8/23
(35%). Examples of positive and negative IHC and
MSI results are given in Figure 1. The percentage of
MMR-deficient breast carcinomas was lower among
MSH6 mutation carriers (2/6, 33% by IHC and 0/7 by
MSI analysis) compared to carriers of MSH2 (3/3,
100% and 3/5, 60%, respectively) or MLH1 mutation
(8/11, 73% and 5/11, 45%, respectively) (statistically
not significant). Breast carcinomas with abnormal
MMR by IHC, MSI, or both were diagnosed at an ear-
lier mean age compared to those with normal MMR
(53 years versus 61 years, P = 0.027). Abnormal MMR
was significantly more frequent in breast carcinomas
from mutation carriers than in those from non-car-
riers (13/20, 65% versus 0/14, 0%, P = 0.00016 by
Fisher’s test) (Table 1).
TSG promoter methylation
Among 24 TSGs investigated, the average number of
genes showing promoter methylation in breast carcino-
mas from mutation carriers was 2.3 per tumor, which
was comparable to non-carriers and sporadic cases
(Table 1). The most frequently methylated genes were
RASSF1 (65%), APC (43%), CDH13 (35%), GSTP1 (17%),
and CDKN2B (17%), and the pattern was quite similar
in breast carcinomas from mutation carriers, non-car-
riers and sporadic ductal cases (Figure 2). Ductal and
lobular breast cancers showed some differences in rela-
tive frequencies of methylation at promoters of indivi-
dual TSGs (Figure 2). In particular, CDKN2B
methylation was more common in lobular than ductal
breast carcinoma at a borderline level of significance
(10/22, 45% versus 14/64, 22% with all groups included,
P = 0.052 by Fisher’s test).
Comparison of different tumors from MMR gene
mutation carriers
Evaluation of the MMR status in eight different tumor
types from MMR gene mutation carriers showed that
breast carcinoma had the lowest frequency of MMR
protein inactivation and the second lowest frequency of
MSI (Figure 3A). TSG promoter methylation revealed
organ-specific profiles (Figure 3B). The top five genes
affected by methylation in breast carcinoma were
involved with variable frequencies in the other tumor
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Figure 1 Outcome of MSI and IHC analyses in three breast tumors from MLH1 mutation carriers. Left, MLH1 expressing, MSS breast
carcinoma from individual 3:60 (Table 2). Middle, ductal carcinoma from the right breast from individual 77:15, displaying MLH1 protein loss and
MSI. Right, lobular carcinoma from the left breast of the same patient, showing MLH1 protein loss and stable microsatellites. Red arrow in IHC
stainings denotes lack of expression in tumor cells and green arrow positive expression in normal cells. MSI results are based on BAT25. IHC,
immunohistory; MSI, microsatellite instability; MSS, microsatellite stable.
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Figure 2 TSG methylation profiles in breast tumors from MMR gene mutation carriers, non-carriers and sporadic cases. Breast
carcinomas from MMR gene mutation carriers and non-carriers were mostly ductal (Table 1) whereas sporadic cases were divided into ductal
and lobular subgroups. Only TSGs which showed promoter methylation in at least 10% of tumors from any group (carriers, non-carriers,
sporadic) were included in this comparison. MMR, mismatch repair; TSG, tumor suppressor gene.
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Figures 3 MMR status and TSG methylation in eight different tumor types from mutation carriers. A, for MMR status comparisons, the
frequencies of MSI and abnormal IHC in the same tumors are indicated. B, Among TSGs, the top five loci affected by methylation in breast
cancer were chosen for display. Dm >0.25 was used as a cut-off for methylation for all tumors. The average number of methylated TSGs out of
24 per tumor is given below each tumor type. Dm, methylation dosage ratio; IHC, immunohistochemistry; MMR, mismatch repair; MSI,
microsatellite instability; TSG, tumor suppressor gene.
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types, too, except for CDKN2B which was methylated in
breast carcinoma only. In regard to the average number
of methylated TSGs out of 24 per tumor, breast carci-
noma (2.3) was the third from top (after 3.3 for stomach
and 2.5 for colon cancer; Figure 3B).
Discussion
Genetic and clinical heterogeneity characterize LS and
manifest themselves in the wide spectrum of cancers
that can be found in LS families [1,34]. We set out to
address whether breast carcinoma is part of the LS
tumor spectrum based on molecular characteristics of
the individuals and tumors. To our knowledge, our
study is the first to compare breast carcinomas from
mutation carriers to those from proven non-carriers
(phenocopies) and to sporadic breast carcinomas from
the same population. This setting provides a reliable
reference for the background rates of the alterations
examined. For example, many cancers that occur in LS
are also common in the general population, reflecting
the combined effect of low-penetrance susceptibility
alleles and environmental factors [35]. Moreover, the
pattern of organ involvement has changed over time
including, for example, a relative decline in stomach
cancer and an increase in colorectal cancer incidence in
more recent generations [36] and may vary according to
the ethnic or geographic origin [13,37], suggesting that
the LS tumor spectrum is sensitive to environmental
influences. The present utilization of representative sets
of other tumors from carriers of the same mutations
additionally makes it possible to recognize the important
role that the tissue of origin may play as a mediator of
the effects of MMR deficiency [38] or epigenetic dysre-
gulation [39]. Finally, previous molecular studies on LS-
associated breast carcinoma have mainly focused on the
MMR status; we additionally evaluated the epigenetic
profiles of the tumors.
Our previous epidemiological investigation of MMR
gene mutation carriers from Finnish LS families [5]
arrived at a standardized incidence ratio of 1.4 for breast
cancer compared to the general population, suggesting
that breast cancer incidence is not elevated in Finnish
LS families. This finding is in agreement with most
reports from other populations (see Introduction). In
the present study, breast carcinoma was diagnosed at 56
years of age in carriers and 54 years in non-carriers,
which is comparable to sporadic breast carcinomas from
our population (59 years) [33]. In the available literature,
the average age of breast carcinoma diagnosis in MMR
gene mutation carriers varies between 46 years and 66
years, including both early-onset series [6,18,40] and ser-
ies with the age at onset similar to the general popula-
tion [8,17]. Interestingly, the age at diagnosis was
significantly lower for MMR-deficient- (53 years) versus
MMR-proficient breast carcinomas (61 years) among
mutation carriers from our study. Combined with the
normal life-time risk of breast cancer in our LS families,
the finding is compatible with the idea that MMR
defects might preferentially be involved in breast cancer
progression rather than initiation [6]. The breast carci-
nomas we studied from MMR gene mutation carriers
were predominantly ductal, ER- and PR-positive and
HER2-negative, resembling breast carcinomas from non-
carriers (Table 1) and those from the unselected Finnish
population [33,41]. Similar to our findings, ductal histol-
ogy predominates in published reports on LS-associated
breast carcinomas [17-19]. While the hormone receptor
or HER2 status has seldom been specified in previous
papers, a single study [19] found predominant hormone
receptor negativity among MMR-deficient breast cancers
from MMR gene mutation carriers; furthermore, there
was no difference in the age at onset between MMR-
deficient and MMR-proficient breast cancers. Apart
from possible population-specific differences, reasons for
the conflicting results relative to ours are unknown.
Apparent selectivity in tumor spectrum despite ubi-
quitous expression is a puzzle shared by a majority of
high-penetrance susceptibility genes, including the
MMR genes in LS. In theory, the LS tumor spectrum
could be influenced by the predisposing gene and muta-
tion (for example, carriers of MSH2 mutation may have
a higher risk of various extracolonic tumors compared
to MLH1 mutation carriers [6]). MMR gene dosage,
which affects the extent and degree of the MMR defect,
is also important, both constitutionally (for example,
biallelic germline mutations are associated with a dis-
tinct tumor spectrum characterized by hematological
and central nervous system malignancies, [42]) and
somatically (for example, DNA damage signaling
requires a higher dosage of MMR protein than DNA
mismatch repair [43] and inactivation of both alleles of
a MMR gene may, therefore, not always be necessary in
tumor cells). Different target genes are rate-limiting in
different cancers and their susceptibility to mutations
and selective advantage conferred by the mutations may
vary (for example, TGFBRII and PTEN both contain
coding repeats which are structurally prone to frame-
shift mutations in the context of deficient MMR, but
TGFBRII is mainly involved in gastrointestinal cancers
and PTEN in endometrial cancer [44]. Finally, different
organs may be differently exposed to exogenous (for
example, dietary carcinogens) or endogenous agents (for
example, hormone-induced oxidative stress) and
removal of such damage may depend on functional
MMR [45,46].
In our study, 65% (13/20) of breast carcinomas from
MMR gene mutation carriers showed loss of the MMR
protein corresponding to the germline mutation and
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35% (8/23) had high-degree MSI. In comparison with
other tumors from MMR gene mutation carriers, the
percentage of breast carcinomas with MMR protein
inactivation was consistently lower and the proportion
with MSI-H in the lower range (Figure 3A). The fact
that MSH6 mutations were overrepresented among
patients with breast carcinomas (7/23, 30%) versus other
tumors (4/105, 4%) might have some influence on the
results since the percentage of MMR-deficient breast
carcinomas was lower among MSH6 than MSH2 or
MLH1 mutation carriers (Table 2). Importantly, we
observed that a given MMR gene mutation could be
associated with MMR proficient breast carcinomas in
some carriers and MMR-deficient breast carcinomas in
other carriers of the same mutation (see Table 2 and
Figure 1 for examples), ruling out the possibility that
normal protein expression or microsatellite-stability was
a general characteristic of these mutations. We conclude
that breast carcinomas from MMR gene mutation car-
riers conformed to other LS tumors in that IHC analysis
of MMR protein expression was more sensitive than
MSI analysis to detect a MMR defect but deviated from
the remaining tumors in that even IHC failed to detect
a MMR defect in a considerable proportion (35%)
arguing against biallelic inactivation in those cases. Even
so, the proportion of MMR-deficient breast carcinomas
was significantly higher compared to breast carcinomas
from non-carriers (Table 1) suggesting that MMR
defects do play a role in breast tumorigenesis in MMR
gene mutation carriers. Furthermore, as discussed above,
the possible role of MMR gene malfunction in processes
other than MMR cannot be completely excluded in the
case of MMR-proficient tumors.
The role of growth-regulatory target genes was
addressed through studies of promoter methylation,
which is known to be an important mechanism of inac-
tivation of the TSGs examined [25,47]. The average
number of methylated TSGs out of 24 was in the upper
range in breast carcinomas among all tumors from
MMR gene mutation carriers (Figure 3B). The five most
frequently methylated TSGs (RASSF1, APC, CDH13,
GSTP1, and CDKN2B) were the same in all groups of
breast cancer (Figure 2) and, with the exception of
CDKN2B, were involved in other tumors from LS
patients, too, although with variable frequencies (Figure
3B). CDKN2B promoter methylation may be a particular
characteristic of breast tumorigenesis as also supported
by observations from other groups [48].
Conclusions
Our findings combined with available literature suggest
that breast carcinoma arising in MMR gene mutation
carriers resembles common breast carcinoma with
respect to life-time risk, clinicopathological features, and
TSG methylation profiles. Significantly higher frequen-
cies of MMR-deficiency distinguish breast carcinomas
from MMR gene mutation carriers from those from
proven non-carriers and sporadic cases. The data as a
whole suggest an association between breast cancer and
inherited MMR deficiency (LS), but appropriate caution
is warranted in interpretations because of the relatively
small numbers of cases investigated and the variability
between individual studies. Clinically, the results are
important for the establishment of LS diagnosis espe-
cially in families lacking typical LS spectrum tumors; in
such cases, IHC analysis of breast carcinoma may be
valuable to pinpoint the predisposing gene. The fact that
breast carcinoma may develop as a consequence of the
predisposing MMR gene defect needs to be taken into
account in the counseling of female MMR gene muta-
tion carriers [49]. Mutation carriers should be encour-
aged to actively participate in population-based breast
screening programs, which typically target women aged
50 years and over [50].
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amplification; PCR: polymerase chain reaction; PMS2: human post meiotic
segregation increased homolog 2; PR: progesterone receptor; PTEN: human
phosphatase and tensin homolog; RASSF1: human ras association (RalGDS/
AF-6) domain family member -1; TGFBRII: human transforming growth factor:
beta receptor II; TSG: tumor suppressor gene.
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